Analysis of Fixed-Dose Combination Products Approved by the US Food and Drug Administration,2010-2015

Abstract

Background:

Fixed-dose combination (FDC) drugs have been an attractive product in pharmaceutical markets because of their unique advantages, but general guidance directing the clinical development of FDC drugs is not yet available in the US.

Method:

All drug approval reports of FDC products approved by the US FDA from January 2010 to December 2015 were intensively analyzed to investigate the regulatory requirements of the US FDA.

Result:

Through analyzing 63 approved FDCs out of 655 New Drug Application (NDA) approvals, it was found that completion of the full phases of clinical trials was not always required for approval by the FDA, which indicates that some phases of clinical studies can be possibly exempted, if justified.

Conclusion:

The results imply that pharmaceutical companies can accelerate FDC development and enter the market earlier if scientific regulatory rationales are established.

Keywords

fixed-dose combination regulatory clinical NDA FDA approval

Get full access to this article

View all access options for this article.

References

Harapanhalli

. CMC considerations for the fixed-dose combination drugs. Paper presented at: AAPS Workshop on Challenges in Developing Fixed-dose Combination Oral Solid Dose Products; September 13-14, 2006; Arlington, VA.

World Health Organization. Annex 5, Guidelines for registration of fixed-dose combination medicinal products [WHO Technical Report 2]. http://apps.who.int/prequal/info_general/documents/TRS929/WHO_TRS_929_annex5FDCs.pdf. Published 2005. Accessed February 2015.

Kararli

Sedo

Bossart

. Fixed-Dose Combinations. Fixed-dose combination products—a review (part 2: Analysis). http://www.drug-dev.com/Main/Back-Issues/FIXEDDOSE-COMBINATIONS-FixedDose-Combination-Produ-673.aspx. Posted April 2014. Accessed March 2015.

Pourkavoos

. Unique risks, benefits, and challenges of developing drug-drug combination products in a pharmaceutical industrial setting. Comb Prod Ther. 2012;2:2.

European Medicines Agency. EMA/CHMP/281825/20152. Committee for Human Medicinal Products (CHMP). Guideline on clinical development of fixed combination medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/05/WC500186840.pdf. Published May 2015. Accessed March 2016.

Sawicki-Wrzask

Thomsen

Bjerrum

. An analysis of the fixed-dose combinations authorized by the European Union, 2009-2014: a focus on benefit-risk and clinical development conditions. Therapeutic Innovation & Regulatory Science. 2015;49:553–559.

Gautam

Bjerrum

Schmiegelow

. The wider use of fixed-dose combinations emphasizes the need for a global approach to regulatory guideline development [published online July 28, 2014]. Therapeutic Innovation & Regulatory Science.

US Food and Drug Administration. Guidance for Industry: nonclinical safety evaluation of drug or biologic combinations. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079243.pdf. Accessed March 2016.

Code of Federal Regulations. Title 21, 21CFR3.2 (e). Combination products.

10.

Electronic Code of Federal Regulations. Title 21, §300.50 Fixed-combination prescription drugs for humans. http://www.ecfr.gov/cgi-bin/text-idx?SID=cb5fbc01d0cbda002e2af9bb46a94e3b&mc=true&node=sp21.5.300.b&rgn=div6#se21.5.300_150.

11.

US Food and Drug Administration. Guidance for industry. Fixed dose combinations, co-packaged drug products, and single-entity versions of previously approved antiretrovirals for the treatment of HIV. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079742.pdf. Accessed February 2016.

12.

US Food and Drug Administration. Guidance for industry. Codevelopment of two or more unmarketed investigational drugs for use in combination. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm236669.pdf. Accessed March 2016.

13.

Electronic Code of Federal Regulations. Title 21, Part 312—Investigational new drug application: subpart B—investigational new drug application (IND). http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=afd2cdce094c53a337ae11f9fcda7761&mc=true&n=pt21.5.312&r=PART&ty=HTML

14.

US Food and Drug Administration. Drugs@FDA. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.

15.

US Food and Drug Administration. Center for Drug Evaluation and Research, Guidance: Applications Covered by Section 505(b)(2). October 1999.

16.

ClinicalTrials.gov . A service of the US National Institutes of Health. http://clinicaltrial.gov.

17.

European Medicines Agency. European Public Assessment Report (EPAR). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d125. Accessed March 2016.

18.

US Food and Drug Administration. Juvisync. Application number: 202343Prig1s000. Medical Review(S). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202343Orig1s000MedR.pdf. Accessed February 2016.

19.

US Food and Drug Administration Guidance for industry. Formal meetings between FDA and sponsors or applications. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER) http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm153222.pdf. Accessed March 2016.

20.

Coccheto

. Regulatory decision-making in the United States based on a single pivotal clinical study: principles and precedents. Clin Res Regul Aff. 2004;21:101–143.

21.

Elliot

. Rationale for a single-pill combination of perindopril arginine and amlodipine besylate. J Am Soc Hypertens. 2015;9:257–265.

22.

Swit

. Strategies in designing clinicals for fixed-combination drugs. Paper presented at: Drug Information Association 42nd Annual Meeting; 2006; Philadelphia, PA.

23.

Elliott

Whitmore

Feldstein

Bakris

. Efficacy and safety of perindopril arginine + amlodipine in hypertension. J Am Soc Hypertens. 2015;9:266–274.

24.

Lewin

DeFronzo

Patel

Liu

Kaste

Woerle

. Initial combination of Empagliflozin and linagliptin in subjects with type 2 diabetes [published online January 29, 2015]. Diabetes Care. DOI: https://dx-doi-org.web.bisu.edu.cn/10.2337/dc14-2365.

25.

Aronson

. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin. Curr Med Res Opin. 2015;31:901–911.

26.

Ansell

. The future for fixed combination product development. Business Dev Licensing J. Issue 13. September 2010. www.plg-uk.com.